Clobazam - Lundbeck

Drug Profile

Clobazam - Lundbeck

Alternative Names: Onfi

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Lundbeck Inc
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • Phase III Dravet syndrome

Most Recent Events

  • 12 Oct 2015 No recent reports on development identified - Phase-III for Lennox-Gastaut syndrome (Adjunctive treatment, In children, In adults) in Australia, Belarus, Lithuania and India (PO)
  • 22 Mar 2015 Lundbeck initiates enrolment in a phase III trial in Dravet syndrome (Adjunctive treatment, In infants, In children, In adolescents) in USA (NCT02187809)
  • 17 Mar 2015 Phase-III clinical trials in Dravet syndrome (In infants, In children, In adolescents, Adjunctive treatment) in USA, Argentina and Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top